34108-13-9

Basic information

• Product Name: 4-benzylidene-2-(4-methoxyphenyl)-1,3-oxazol-5(4H)-one
• CAS NO: 34108-13-9
• Molecular Formula: C₁₇H₁₃NO₃
• Molecular Weight: 279.29
• Mol File: 34108-13-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 420.5°C at 760 mmHg
• Flash Point: 186.6°C
• Density: 1.18g/cm³
• Vapor Pressure: 2.81E-07mmHg at 25°C
• Refractive Index: 1.594
• CAS DataBase Reference: 4-benzylidene-2-(4-methoxyphenyl)-1,3-oxazol-5(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-benzylidene-2-(4-methoxyphenyl)-1,3-oxazol-5(4H)-one(34108-13-9)
• EPA Substance Registry System: 4-benzylidene-2-(4-methoxyphenyl)-1,3-oxazol-5(4H)-one(34108-13-9)

Safety Data

• Hazardous Substances Data: 34108-13-9(Hazardous Substances Data)

Upstream product

• 100-52-7 benzaldehyde 
• 13214-64-7 N-(4-methoxybenzoyl)glycine 
• 103678-74-6 N-(4-methoxybenzoyl)-phenylalanine 
• 217446-35-0 4-benzyl-2-(4-methoxyphenyl)-5-oxo-4,5-dihydrooxazole 

Downstream Products

• 86818-85-1 2-(4-Methoxy-phenyl)-3-(4-morpholin-4-yl-phenyl)-5-[1-phenyl-meth-(Z)-ylidene]-3,5-dihydro-imidazol-4-one 
• 59490-36-7 (2S)-methyl 2--3-phenyl-1-propanoate 
• 59490-27-6 methyl (Z)-2-(4-methoxybenzamido)-3-phenylacrylate 
• 1323140-70-0 C₂₂H₂₃ClN₂O₃ 
• 1323141-15-6 C₂₂H₂₄N₂O₃ 

Relevant articles and documents

Synthesis and Biological Evaluation of New Diarylpyrazole and Triarylimidazoline Derivatives as Selective COX-2 Inhibitors

New series of diarylpyrazoles 8a–f and triarylimidazoline-5-ones 11a–g were synthesized and evaluated for their in vitro cyclooxygenase-1 (COX-1) and COX-2 inhibitory activity and in vivo anti-inflammatory activity. The synthesized compounds showed good selectivity for COX-2; compounds 8a, 8d, 8f, 11a, and 11c exhibited the highest COX-2 selectivity indexes (SI = 4.77–5.43) compared to the reference drug celecoxib (SI = 7.8). All compounds showed good in vivo anti-inflammatory activity, especially compounds 8a, 8f, 11c, and 11d, which also showed some similarities to the time interval pattern of celecoxib at all different time intervals (1, 3, and 6 h).

Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis

Disclosed are compounds of the Formula I and their use in a method of inhibiting the aggregation of amyloid proteins and in a method of imaging amyloid deposits.

Synthesis and anti-inflammatory effect of 1-ethoxycarbonylmethylimidazolin-5-onic derivatives

-